Cancer52 Patient Survey Data
We are pleased to share the data breakdown from the Cancer52 Patient Survey, conducted in summer 2024. Cancer52 Patient Survey Data If...
top of page
Cancer52 is looking for new trustees!
A number of trustees have reached the end of their period of appointment, and we are looking for three people to join our Board. The Role...
Genomics England hosts Cancer52 Roundtable
Genomics England recently hosted a roundtable event with many Cancer52 members including: Sarcoma UK, Young Lives vs Cancer, Myeloma UK,...
Cancer52 Health Inequalities Report
Cancer52 has released its latest report on health inequalities , as part of the Big Cancer52 Conversation event. >> Read report...
Fair Market Value (FMV) Guidance
Fair Market Value (FMV) Guidance is now available to bring consistency to reimbursement for cross-sector partnership work. See FMV...
Cancer52 prepares briefing for debate on a future cancer strategy for England
Cancer52 has prepared a briefing for a Westminster Hall Debate on the ‘Potential merits of a cancer strategy for England’ . The debate...
New member: The Sophie Fitzpatrick Charitable Foundation for Rare Cancers
We are delighted to welcome a new member! The Sophie Fitzpatrick Charitable Foundation for Rare Cancers.
Patient Organisation Statement on NHS England Commercial Framework Consultation, September 2024
Patient Organisation Statement on NHS England Commercial Framework Consultation
Cancer52 meets with Minister for Cancer
Interim CEO, Sasha Daly was pleased to meet with Minister Andrew Gwynne to talk through cancer services and how Cancer52 can work in partner
New CEO for Cancer52!
Cancer52 is delighted to announce the appointment of Chris Walden as our new CEO.
bottom of page